Association between plasma complement factor H concentration and clinical outcomes in patients with sepsis

Junji Shimizu (jushimi77@gmail.com)
Shiga University of Medical Science
https://orcid.org/0000-0001-6287-6137

Kazunori Fujino
Department of Critical and Intensive Care Medicine, Shiga University of Medical Science

Toshihiro Sawai
Department of Pediatrics, Shiga University of Medical Science

Yasuyuki Tsujita
Emergency and Intensive Care Unit, Shiga University of Medical Science

Takahisa Tabata
Department of Critical and Intensive Care Medicine, Shiga University of Medical Science

Yutaka Eguchi
Department of Critical and Intensive Care Medicine, Shiga University of Medical Science

Research

Keywords: Complement, Complement factor H, sepsis, organ dysfunction, coagulation, central nervous system

DOI: https://doi.org/10.21203/rs.3.rs-52212/v1

License: ☺️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background The complement system is important for defending against pathogens; however, excessive complement activation is associated with a poor prognosis and organ dysfunction in sepsis. Complement factor H (CFH) acts to prevent excessive complement activation and damage to the self through the regulation of the complement alternative pathway.

This study aimed to investigate the association between plasma CFH levels on admission to the ICU and 90-day mortality and organ dysfunction, in patients with sepsis.

Methods This is a single-center prospective observational study conducted from July 2016 to March 2019. Logistic regression analysis and correlation analysis were performed to assess the relationship between the plasma CFH on admission to the ICU and 90-day mortality, and organ dysfunction.

Results This analysis included 62 patients. The plasma CFH levels were significantly lower in 90 day non survivors than those in survivors (70.0 μg/ml [interquartile range (IQR) 51.2 - 97.6] vs 104.8 μg/ml [IQR 66.8 - 124.2], P=0.006). The plasma CFH levels were associated with 90 day mortality (OR 0.977 95% CI 0.957 – 0.994, p = 0.01). Correlation analysis showed that the plasma CFH levels were negatively correlated with the Physiology and Chronic Health Evaluation II (APACHE II) score, Sequential Organ Failure Assessment (SOFA) score and Simplified Acute Physiology Score 2 (SAPS 2) (r= -0.35, P=0.005; r=-0.28, P=0.026; r=-0.30, P=0.019, respectively). Regarding the SOFA scores for each organ, those for the coagulation and neurological components were negatively correlated with the CFH concentration (r=-0.33, P=0.010; r=-0.25, P=0.046, respectively).

Conclusion Lower plasma levels of CFH were associated with sepsis severity and mortality and were correlated with the coagulation and neurological components of the SOFA score in patients with sepsis on admission to the ICU.

Introduction

Sepsis is a leading cause of morbidity and mortality among critically ill patients and a major global medical problem. Its mortality rate has been estimated to exceed 30% [1, 2]. Recently, sepsis was defined as life-threatening organ dysfunction caused by a dysregulated host response to infection [3]. The complement system is an essential component of the innate immune system [4-6]. Activation of the complement system occurs through three pathways: the classical pathway, the lectin pathway, and the alternative pathway [5, 6]. Complement factor H (CFH) is the major negative regulator of the alternative pathway [7]. CFH acts to prevent excessive complement activation and damage to the self through the repression of the complement alternative pathway [8, 9]. Abnormalities in CFH causing the dysregulation of the alternative pathway have been involved in the pathogenesis of atypical hemolytic uremic syndrome (aHUS), which is a type of thrombotic microangiopathy[10, 11].
The rapid activation of the complement system plays an important role in defending against pathogens; however, the excessive complement activation in sepsis has been reported to produce the detrimental effects; including neutrophil dysfunction [12,13], coagulopathy [14], and organ failure, leading to a poor outcome [15]. However, it is unclear whether CFH is associated with severity, mortality and organ dysfunction in patients with sepsis. The objective of this study was to assess the association of CFH with 90-day mortality, sepsis severity and organ dysfunction, including coagulopathy, in patients with sepsis upon admission to the ICU.

**Materials And Methods**

**Study design and population**

We conducted a single-center prospective observational study from July 2016 to March 2019 in the surgical and medical intensive Care Unit (ICU) of Shiga University of Medical Science, Japan. Subjects were sepsis patients admitted to that ICU. Sepsis was defined according to the Third International Consensus Definitions for Sepsis and Septic Shock [3]. The exclusion criterion was age of < 18 years. The patients were followed for 90 days. Written informed consent to participate in this study was obtained from the patients or their relatives. The protocols for this study were approved by the Scientific-Ethical Committees of Shiga University of Medical Science (protocol ID R2015-220), and adhered to the Declaration of Helsinki principles.

**Measurements and outcome**

The following data were collected: age, sex, platelet count, PT activity, activated partial thromboplastin time (APTT), fibrinogen level, white blood cell count, C-reactive protein (CRP) level, lactate level, Acute Physiology and Chronic Health Evaluation (APACHE) II score [16], Sequential Organ Failure Assessment (SOFA) score [17], Simplified Acute Physiology Score (SAPS) II [18], and 90-day mortality. The main prognostic outcome was 90-day mortality. The correlations of CFH with each SOFA score and the correlations of CFH with the coagulation test results were investigated.

**Blood collection**

Blood samples were collected within 24 hours of admission to the ICU. The blood platelet count and white blood cell count were assessed using samples collected in EDTA tubes, and CRP was measured in samples collected in vacuum blood collection tubes with coagulation accelerators and serum separators. Coagulation tests including PT activity, APTT, and fibrinogen were performed with samples collected in sodium citrate tubes. Lactate was measured with blood gas analysis. These blood sample measurements were performed in the hospital’s central laboratory.

**Plasma CFH measurement**

The plasma CFH level was measured with a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Hycult Biotech, Pennsylvania, USA) in accordance with the manufacturer’s instructions. Blood
samples were collected in vacutainers containing EDTA. The samples were then centrifuged at 3000 rpm for 10 minutes at room temperature. Immediately after centrifugation, the plasma was collected and stored at -80°C until measurement.

**Statistical analysis**

Data are presented as either frequencies and percentages for categorical variables or medians and interquartile ranges (IQRs) for continuous variables. The chi-squared test or Fisher's exact test was used for the comparison of categorical variables, while the Mann-Whitney U test was used for the comparison of continuous variables. Univariate and multivariate analyses were performed using logistic regression analysis. Receiver operating characteristic (ROC) curve analysis was carried out to evaluate the predictive accuracy. Spearman's test was used for correlation analysis. All tests were two tailed, and p values less than 0.05 indicated statistical significance. Data were analyzed using SPSS software, version 25 (IBM Corp., Armonk, NY, USA).

**Results**

**Study patients**

A total of 109 patients met the inclusion criteria. Written informed consent was obtained from 62 of those patients, and those patients were included in the analysis. The characteristics of the patients included in this study are shown in Table 1. The median age was 75 [interquartile range (IQR) 68 – 80] years, and the SOFA score, SAPS 2, and APACHE II score, which are indicators of severity, were 9 [IQR 7 – 12], 55 [41-63] and 23 [16 – 28], respectively. Eighteen patients (29.0%) died within 90 days. In the comparison of 90-day survivors and nonsurvivors, age and all severity scores were significantly higher in 90-day nonsurvivors. Inflammatory markers such as the WBC count and levels of CRP and lactate were not different between the two groups on admission to the ICU; however, the plasma level of fibrinogen was significantly lower in the nonsurvivors than in the survivors. The other coagulation markers did not differ between the two groups.

**Table 1** Patient characteristics
Patient characteristics

|                  | Total, N = 62 | 90-day survivors, N = 44 | 90-day nonsurvivors, N = 18 | p value |
|------------------|---------------|--------------------------|-----------------------------|---------|
| Age, years       | 75 (68 - 80)  | 72 (67 - 77)             | 77 (72 - 82)                | 0.022   |
| Male sex, n (%)  | 42 (67)      | 29 (66)                  | 13 (72)                     | 0.629   |
| APACHE-II score  | 23 (16 - 28) | 18 (14 - 27)             | 27 (22 - 34)                | 0.003   |
| SOFA score       | 9 (7 - 12)   | 9 (6 - 10)               | 12 (9 - 14)                 | 0.001   |
| SAPS 2 score     | 55 (41 - 63) | 49 (35 - 57)             | 63 (55 - 68)                | 0.002   |
| Platelet count, ×10^9/l | 154 (103 - 231) | 158 (119 - 269) | 121 (68 - 195) | 0.166   |
| PT activity, %   | 63 (53 - 76) | 61 (53 - 73)             | 64 (53 - 87)                | 0.375   |
| APTT, seconds    | 39 (33 - 48) | 39 (33 - 45)             | 41 (32 - 52)                | 0.633   |
| Fibrinogen, g/l  | 378 (274 - 524) | 417 (308 - 540) | 320 (172 - 421) | 0.026   |
| White blood cell count, /μl | 14.7 (9.3 - 19.9) | 14.2 (9.9 - 19.5) | 15.3 (8.5 - 19.9) | 0.816   |
| CRP, mg/dl       | 8.6 (5.4 - 18.7) | 9.5 (6.1 - 20.4) | 7.6 (5.0 - 17.8) | 0.174   |
| Lactate, mg/dl   | 18.0 (12.0 - 37.0) | 17.0 (12.5 - 33.5) | 22.5 (11.0 - 52.0) | 0.433   |

APACHE-II Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment, SAPS 2 Simplified Acute Physiology Score, CRP C-reactive protein

Plasma levels of complement factor H and 90 day mortality

Overall, the median plasma CFH level was 94.1 μg/ml [IQR 61.6 - 120.0], and the CFH level was significantly lower in nonsurvivors than in survivors, with values of 70.0 μg/ml [IQR 51.2 - 97.6] and 104.8 μg/ml [IQR 66.8 - 124.2], respectively (P=0.006) (Figure 1). In univariate logistic regression analysis, age, SOFA score and CFH level were associated with 90-day mortality (OR 1.097, 95% CI 1.016 - 1.185, p = 0.02, OR 1.415 95% CI 1.140 – 1.755, p = 0.02, OR 0.977 95% CI 0.957 – 0.994, p = 0.01). A multivariable logistic regression analysis with age and SOFA score as confounders showed that the plasma CFH levels were not independently associated with 90-day mortality (Table 2). To assess the diagnostic accuracy of CFH for the prediction of 90-day mortality, receiver operating characteristic analysis was performed and showed that the CFH level had significant predictive value, with an area under the curve (AUC) of 0.724 (95% CI, 0.587 – 0.862) (Fig. 2).

Table 2 Univariable and multivariable logistic regression analysis for 90-day mortality

|                  | Univariable analysis | Multivariable analysis |
|------------------|----------------------|------------------------|
|                  | OR 95% Confidence interval | P value | aOR 95% Confidence interval | P value |
| Age, years       | 1.097 | 1.016 - 1.185 | 0.02 | 1.124 | 1.005 - 1.256 | 0.04 |
| SOFA score       | 1.415 | 1.140 - 1.755 | 0.02 | 1.432 | 1.099 - 1.865 | 0.01 |
| CFH (μg/ml)      | 0.977 | 0.957 - 0.994 | 0.01 | 0.986 | 0.965 - 1.008 | 0.205 |

CFH Complement factor H, OR odds ratio, aOR adjusted odds ratio

Correlation analysis between CFH and severity scores and coagulation factors

Correlation analysis showed that the plasma CFH levels were negatively correlated with the severity scores, namely, the APACHE II score, the SOFA score and the SAPS 2 (r= -0.35, P=0.005; r= -0.28, P=0.026; r= -0.30, P=0.019, respectively) (Figure 3). In the individual SOFA scores for each organ, the scores for the coagulation and neurological components were negatively correlated with the CFH level (r=-0.33, P=0.010;
r=-0.25, P=0.046, respectively) (Figure 4). Plasma CFH levels were positively correlated with the fibrinogen level and PT activity (r=0.31, P=0.015; r=0.32, P=0.012, respectively) and negatively correlated with the APTT (r=-0.35, P=0.007) (Figure 5).

**Discussion**

In this study, plasma levels of CFH on admission to the ICU were related to severity and mortality in patients with sepsis. The CFH level was correlated with the coagulation and neurological components of the SOFA score and with the fibrinogen level, PT activity and APTT. To our knowledge, this is the first report showing an association between the CFH level and the prognosis of and organ damage in sepsis in a clinical setting.

Our study showed that the plasma levels of CFH were lower in the 90-day nonsurviving group than in the surviving group and were negatively correlated with severity score. Previous studies have reported organ damage due to excessive complement activation in sepsis[19 - 22]. Among the complement components, C3a, C4a, C5a and membrane attack complex (MAC) have been reported to be associated with coagulopathy, organ dysfunction and prognosis [23 - 27]. These complement components and terminal complement complexes are regulated by CFH [7, 8]. Taken together, the decreased plasma CFH concentrations may have resulted in dysregulated complement activation, leading to a worse prognosis.

Concerning coagulation abnormalities, our study showed that lower plasma concentrations of CFH were associated with lower PT activity, lower fibrinogen levels, prolonged APTT and the coagulation components of the SOFA score. Recently, immunothrombosis and immunohemostasis processes involving the innate immune system have been identified as helping prevent the dissemination of and tissue invasion by pathogens [28, 29]; however, excessive activation leads to the development of disseminated intravascular coagulation (DIC), which is characterized by systemic coagulation activation and organ dysfunction due to disordered microcirculation [30]. These coagulation systems have been reported to interact with the complement system, [31 - 34], and excessive complement activation has been reported to be associated with sepsis-associated DIC and a poor prognosis [27, 35, 36]. Mutations of CFH or CFH autoantibodies are causes of aHUS, which is known to cause thrombocytopenia and coagulation disorders [10,11,37, 38]. In this context, the association of lower plasma concentrations of CFH with lower PT activity, lower fibrinogen levels, prolonged APTT and the coagulation components of the SOFA score shown in this study may suggest abnormal coagulation due to excessive complement activation.

This study found a correlation between the plasma CFH concentration and the neurological components of the SOFA score. Patients with sepsis are known to have complications involving the central nervous system, such as sepsis-associated encephalopathy and sepsis-associated delirium [39,40]. Central nervous system complications are also common in aHUS, which is caused by abnormalities in CFH [41 - 44]. It has been reported that complement activation, including C3 and C5a, is associated with central nervous system dysfunction in sepsis [45 - 47]. C5a is reported to play an important role in the blood-
brain barrier (BBB) breakdown in septic encephalopathy [48]. These previous reports support our finding that a lower plasma CFH concentration is correlated with neurological dysfunction.

The results of the present study have several potential implications for future research. Patients with low CFH levels may have a worse prognosis of sepsis. In clinical practice, it is difficult to distinguish among the C3 species related to the outcome because circulating C3 exists in different sizes [25]. It is also difficult to detect C5a due to its low plasma concentration [13]. CFH is one of the most abundant complement components in human blood [7]; therefore, CFH may represent a potential candidate biomarker for excessive complement activation. The pharmacological enhancement of CFH and the administration of CFH may be therapeutic options for patients with sepsis who present with organ dysfunction or coagulopathy due to excessive complement activation.

A major limitation of this study was the small sample size and the single-center nature of the study. We did not measure any complement components other than CFH. Therefore, it was not possible to determine whether the low levels of CFH actually led to excessive complement activation. The CFH level was correlated with the severity scores; therefore, CFH is not a prognostic factor for 90-day mortality independent of these severity scores. It took three or four hours from the collection of the sample from the arterial line to centrifugation and storage at -80°C, and it is possible that the CFH concentration had changed by the time of measurement. However, all measurements were performed under the same conditions with regard to the time from blood sample collection to measurement, and we believe that the results of the study are reliable.

**Conclusion**

Lower plasma levels of CFH were associated with increased severity and mortality in patients with sepsis on admission to the ICU and were correlated with central nervous system dysfunction and coagulopathy. Further large-sample studies are needed.

**Abbreviations**

CFH: Complement factor H; ICU: intensive care unit; IQR: interquartile range; APACHE II: Acute Physiology and Chronic Health Disease Classification System II; SOFA: Sequential Organ Failure Assessment; SAPS 2: Simplified Acute Physiology Score 2; aHUS: atypical hemolytic uremic syndrome; ROC: receiver operating characteristic; AUC: area under the curve; MAC: membrane attack complex; DIC: disseminated intravascular coagulation; BBB: blood-brain barrier

**Declarations**

**Acknowledgments**

None
Founding

None

Authors' contributions

JS, KF and YE designed the study. The data collection and evaluation were conducted by JS, KF, YT, and YE. TT and TS supported the study design, data collection, and evaluation. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Junji Shimizu

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics declarations

Ethics approval and consent to participate

The study protocol was approved by our local research ethics committee (protocol ID R2015-220), and informed consent was obtained from all participants.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Author information

Affiliations

Emergency and Intensive Care Unit, Shiga University of Medical Science Hospital, Seta Tsukinowa-cho, Otsu, Shiga, Japan

Junji Shimizu, Yasuyuki Tsujita

Department of Critical and Intensive Care Medicine, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga, Japan

Kazunori Fujino, Takahisa Tabata, Yutaka Eguchi
References

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. The New England journal of medicine. 2003;348(16):1546-54.

2. Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. American journal of respiratory and critical care medicine. 2016;193(3):259-72.

3. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama. 2016;315(8):801-10.

4. Muller-Eberhard HJ. Molecular organization and function of the complement system. Annual review of biochemistry. 1988;57:321-47.

5. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nature immunology. 2010;11(9):785-97.

6. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement System Part I - Molecular Mechanisms of Activation and Regulation. Frontiers in immunology. 2015;6:262.

7. Parente R, Clark SJ, Inforzato A, Day AJ. Complement factor H in host defense and immune evasion. Cellular and molecular life sciences : CMLS. 2017;74(9):1605-24.

8. de Cordoba SR, de Jorge EG. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clinical and experimental immunology. 2008;151(1):1-13.

9. Sanchez-Corral P, Gonzalez-Rubio C, Rodriguez de Cordoba S, Lopez-Trascasa M. Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Molecular immunology. 2004;41(1):81-4.

10. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. The New England journal of medicine. 2009;361(17):1676-87.

11. Kaplan BS, Meyers KE, Schulman SL. The pathogenesis and treatment of hemolytic uremic syndrome. Journal of the American Society of Nephrology : JASN. 1998;9(6):1126-33.

12. Ward PA. The dark side of C5a in sepsis. Nature reviews Immunology. 2004;4(2):133-42.

13. Xu R, Lin F, Bao C, Huang H, Ji C, Wang S, et al. Complement 5a receptor-mediated neutrophil dysfunction is associated with a poor outcome in sepsis. Cellular & molecular immunology. 2016;13(1):103-9.

14. Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD. Interactions between coagulation and complement - their role in inflammation. Seminars in immunopathology. 2012;34(1):151-65.
15. Charchaieh J, Wei J, Labaze G, Hou YJ, Babarsh B, Stutz H, et al. The role of complement system in septic shock. Clinical & developmental immunology. 2012;2012:407324.

16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Critical care medicine. 1985;13(10):818-29.

17. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive care medicine. 1996;22(7):707-10.

18. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. Jama. 1993;270(24):2957-63.

19. Charchaieh J, Rushbrook J, Worah S, Zhang M. Activated Complement Factors as Disease Markers for Sepsis. Disease markers. 2015;2015:382463.

20. Rittirsch D, Redl H, Huber-Lang M. Role of complement in multiorgan failure. Clinical & developmental immunology. 2012;2012:962927.

21. Hack CE, Nuijens JH, Felt-Bersma RJ, Schreuder WO, Eereberg-Belmer AJ, Paardekooper J, et al. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. The American journal of medicine. 1989;86(1):20-6.

22. Karasu E, Nilsson B, Kohl J, Lambris JD, Huber-Lang M. Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction. Frontiers in immunology. 2019;10:543.

23. Hack CE, Nuijens JH, Felt-Bersma RJ, Schreuder WO, Eereberg-Belmer AJ, Paardekooper J, et al. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. The American journal of medicine. 1989;86(1):20-6.

24. Zhao X, Chen YX, Li CS. The prognostic performance of the complement system in septic patients in emergency department: a cohort study. Biomarkers in medicine. 2015;9(7):661-8.

25. Cheng TH, Puskarich M, Li X, Fang Z, Xu F, Chen Y, et al. Circulating Complement C3-Alpha Chain Levels Predict Survival of Septic Shock Patients. Shock (Augusta, Ga). 2019.

26. Unnewehr H, Rittirsch D, Sarma JV, Zetoune F, Flierl MA, Perl M, et al. Changes and regulation of the C5a receptor on neutrophils during septic shock in humans. Journal of immunology (Baltimore, Md : 1950). 2013;190(8):4215-25.

27. Abe T, Kubo K, Izumoto S, Shimazu S, Goan A, Tanaka T, et al. Complement Activation in Human Sepsis is Related to Sepsis-Induced Disseminated Intravascular Coagulation. Shock (Augusta, Ga). 2020.

28. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nature reviews Immunology. 2013;13(1):34-45.

29. Delabranche X, Helms J, Meziani F. Immunohaemostasis: a new view on haemostasis during sepsis. Annals of intensive care. 2017;7(1):117.

30. Ito T. PAMPs and DAMPs as triggers for DIC. Journal of intensive care. 2014;2(1):67.
31. Lupu F, Keshari RS, Lambris JD, Coggeshall KM. Crosstalk between the coagulation and complement systems in sepsis. Thrombosis research. 2014;133 Suppl 1:S28-31.

32. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in crime? Trends in immunology. 2007;28(4):184-92.

33. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nature medicine. 2006;12(6):682-7.

34. Muhlfelder TW, Niemetz J, Kreutzer D, Beebe D, Ward PA, Rosenfeld SI. C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. The Journal of clinical investigation. 1979;63(1):147-50.

35. Zhao X, Chen YX, Li CS. Predictive value of the complement system for sepsis-induced disseminated intravascular coagulation in septic patients in emergency department. Journal of critical care. 2015;30(2):290-5.

36. Ren J, Zhao Y, Yuan Y, Han G, Li W, Huang Q, et al. Complement depletion deteriorates clinical outcomes of severe abdominal sepsis: a conspirator of infection and coagulopathy in crime? PloS one. 2012;7(10):e47095.

37. Fujisawa M, Kato H, Yoshida Y, Usui T, Takata M, Fujimoto M, et al. Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. Clinical and experimental nephrology. 2018;22(5):1088-99.

38. Sakurai S, Kato H, Yoshida Y, Sugawara Y, Fujisawa M, Yasumoto A, et al. Profiles of Coagulation and Fibrinolysis Activation-Associated Molecular Markers of Atypical Hemolytic Uremic Syndrome in the Acute Phase. Journal of atherosclerosis and thrombosis. 2020;27(4):353-62.

39. Iacobone E, Bailly-Salin J, Polito A, Friedman D, Stevens RD, Sharshar T. Sepsis-associated encephalopathy and its differential diagnosis. Critical care medicine. 2009;37(10 Suppl):S331-6.

40. Ebersoldt M, Sharshar T, Annane D. Sepsis-associated delirium. Intensive care medicine. 2007;33(6):941-50.

41. Hirt-Minkowski P, Dickenmann M, Schifferli JA. Atypical hemolytic uremic syndrome: update on the complement system and what is new. Nephron Clinical practice. 2010;114(4):c219-35.

42. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet journal of rare diseases. 2011;6:60.

43. Fidan K, Göknar N, Gülhan B, Melek E, Yıldırım ZY, Baskın E, et al. Extra-Renal manifestations of atypical hemolytic uremic syndrome in children. Pediatric nephrology (Berlin, Germany). 2018;33(8):1395-403.

44. Koehl B, Boyer O, Biebuyck-Gouge N, Kossorotoff M, Frémeaux-Bacchi V, Boddaert N, et al. Neurological involvement in a child with atypical hemolytic uremic syndrome. Pediatric nephrology (Berlin, Germany). 2010;25(12):2539-42.

45. Nataf S, Stahel PF, Davoust N, Barnum SR. Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Trends in neurosciences. 1999;22(9):397-402.
46. Jacob A, Hensley LK, Safratowich BD, Quigg RJ, Alexander JJ. The role of the complement cascade in endotoxin-induced septic encephalopathy. Laboratory investigation; a journal of technical methods and pathology. 2007;87(12):1186-94.

47. Annane D. Sepsis-associated delirium: the pro and con of C5a blockade. Critical care (London, England). 2009;13(2):135.

48. Flierl MA, Stahel PF, Rittirsch D, Huber-Lang M, Niederbichler AD, Hoesel LM, et al. Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis. Critical care (London, England). 2009;13(1):R12.

Figures
Plasma levels of CFH and 90-day mortality. Plasma CFH levels were significantly lower in nonsurvivors than in survivors.

Figure 1
Figure 2

ROC curve for CFH as a predictor of 90-day mortality The receiver operating characteristic curve analysis assessing the diagnostic accuracy of CFH for the prediction of 90-day mortality showed that it had significant predictive value.
Figure 2

ROC curve for CFH as a predictor of 90-day mortality. The receiver operating characteristic curve analysis assessing the diagnostic accuracy of CFH for the prediction of 90-day mortality showed that it had significant predictive value.

Figure 3

Correlation analysis between CFH and severity scores. Correlation analysis showed that the plasma CFH levels were negatively correlated with the severity scores, namely, the APACHE II score, SOFA score, and SAPS 2.
Correlation analysis between CFH and severity scores Correlation analysis showed that the plasma CFH levels were negatively correlated with the severity scores, namely, the APACHE II score, SOFA score, and SAPS 2.

**Figure 3**

Correlation analysis between CFH and severity scores Correlation analysis showed that the plasma CFH levels were negatively correlated with the severity scores, namely, the APACHE II score, SOFA score, and SAPS 2.

**Figure 4**
Correlation analysis between CFH and the SOFA score for each organ. The coagulation and neurological components of the SOFA score were negatively correlated with the CFH level.

**Figure 4**

Correlation analysis between CFH and the SOFA score for each organ. The coagulation and neurological components of the SOFA score were negatively correlated with the CFH level.
Figure 5

Correlation analysis between CFH and coagulation test results. The CFH level was positively correlated with the fibrinogen level and PT activity and negatively correlated with the APTT.